Skip to main content
BioCentury Innovations (formerly SciBX)
< Next Issue 1 2 3 4 5 Prior Issue >
As published Thursday, May 21, 2015

By Stephen Parmley, Senior Writer

Aduro Biotech Inc.'s preclinical STING agonists have caught the eye of pharmas for their ability to stimulate immunity in distal tumors, which suggests the compounds might be among the first immunotherapy agents for metastases. Having signed a deal in March with Novartis AG for its immunotherapy program, Aduro has now published two studies revealing how its cyclic dinucleotides harness dendritic cells to ramp up tumor-specific immune responses.

The company believes the compounds could compete in the next wave of therapies designed to boost anti-PD-1 response rates.